# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and anno...
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate o...
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 -
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of ...
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and anno...
Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and s...